Bataille Benoît, Raoudha Bennadji, Le Tinier Florence, Basson Laurent, Escande Alexandre, Langin Hélène, Tresch Emmanuelle, Crop Frederik, Darloy Franck, Carlier Damien, Lartigau Eric, Pasquier David
Academic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France.
Methodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France.
Cancers (Basel). 2020 Dec 20;12(12):3852. doi: 10.3390/cancers12123852.
The objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 Gy in 25 fractions to the breast or chest wall and to lymph node areas, with a simultaneous integrated boost at a dose of 60 Gy at the tumor bed in cases of breast conservative surgery. We included 288 patients, 168 and 120 treated with breast-conserving surgery and mastectomy respectively. Two hundred sixty patients (90.3%) received lymph node irradiation. Median follow-up was 25 months (6-48). Acute dermatitis was observed in 278 patients (96.5%), mostly grade 1 (59.7%). The aesthetic aspect of the breast at one year was reported as "good" or "excellent" in 84.6% of patients. The patients' quality of life improved over time, especially those treated with chemotherapy. The two-year overall survival and disease-free survival were 97.8% (95% confidence interval (CI): 94.1-99.2%), and 93.4% (95% CI: 89.2-96.0%) respectively. Tomotherapy for locally advanced BC has acceptable toxicity, supporting its use in this indication; however, longer follow-up is needed to assess long-term outcomes.
本研究的目的是评估接受断层放射治疗的乳腺癌(BC)患者的急性和中期毒性、生活质量以及美学效果。这是一项前瞻性研究,纳入了接受断层放射治疗的BC患者。放射治疗给予乳房或胸壁以及淋巴结区域50 Gy,分25次进行,对于保乳手术的病例,在瘤床同时给予60 Gy的同步整合加量照射。我们纳入了288例患者,其中168例和120例分别接受了保乳手术和乳房切除术。260例患者(90.3%)接受了淋巴结照射。中位随访时间为25个月(6 - 48个月)。278例患者(96.5%)观察到急性皮炎,大多为1级(59.7%)。84.6%的患者报告一年时乳房的美学外观为“良好”或“优秀”。患者的生活质量随时间改善,尤其是接受化疗的患者。两年总生存率和无病生存率分别为97.8%(95%置信区间(CI):94.1 - 99.2%)和93.4%(95% CI:89.2 - 96.0%)。断层放射治疗局部晚期BC具有可接受的毒性,支持其在该适应证中的应用;然而,需要更长时间的随访来评估长期结果。